FDA Approves BlueBird’s $2.8 Million Gene Therapy for Rare Blood Disease

The Food and Drug Administration approved a gene therapy from Bluebird Bio Inc., a first-of-its kind treatment that represents a potential cure for a rare blood disorder at a price of $2.8 million per treatment.

The FDA on Wednesday cleared the treatment, Zynteglo, for patients who rely on regular blood transfusions because of a genetic disease called beta-thalassemia that interferes with the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

WA pays $2M to workers assaulted at psychiatric hospitalA judge has ordered the state agency that operates Washington’s largest psychiatric hospital to pay more than $2 million to four female health workers who were assaulted by a violent patient who targeted women. FOX13 Move this place to McNeil island
Source: fox13seattle - 🏆 328. / 59 Read more »